SML BIOPHARM
PrivateLast Round
Series B
Jul 21, 2025
Company Overview
SML BIOPHARM is a biotechnology company that develops advanced therapies using mRNA technology to treat a wide range of diseases, including personalized cancer vaccines and therapeutics for infectious and rare diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
SML BIOPHARM Comparables
Compare SML BIOPHARM with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Pantherna Therapeutics | 83% | |
| Genevant Sciences | 77% | |
| Kernalbio | 76% | |
SML BIOPHARM Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jul 21, 2025 | ||||
| Strategic | Dec 7, 2023 |
SML BIOPHARM Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about SML BIOPHARM's valuation, stock price, and market status.